Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Urology, Bladder Cancer |
| Therapuetic Areas: | Nephrology / Urology, Oncology |
| Healthy: | No |
| Age Range: | 25 - Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2012 |
| End Date: | December 2016 |
A Multi-Center Study to Evaluate the Safety and Efficacy of a Urine DEK ELISA in Diagnosis of Subjects With Bladder Cancer
The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in
the urine of patients suspected of having bladder cancer. The measurement of urine DEK
protein, relative to an established cut-off, is correlated with the presence or absence of
bladder cancer.
the urine of patients suspected of having bladder cancer. The measurement of urine DEK
protein, relative to an established cut-off, is correlated with the presence or absence of
bladder cancer.
Sample Collection:
Urine samples used in the study will be collected immediately prior to the urological
evaluation procedure and stored at -80 oC. Urine samples will be sent to sponsor and remain
at -80o C until analysis.
Clinical Data Collection:
All subject and clinical information will be recorded on the form in section 9.3. Enrollment
Checklist and Case Report Form (CRF). Information regarding the history of hematuria and
urine cytology will be recorded. In addition, non-identifying information including age,
sex, race, smoking history, alcohol consumption, occupational exposure to chemicals or dyes,
history of urologic disorder or disease, history of irritative voiding symptoms, history of
urinary tract infection, history of pelvic irradiation, and analgesic abuse will be
recorded. The Investigators will also be asked to provide information from the subjects'
medical records for up to one (1) year after their enrollment and sample collection. In
particular, diagnosis of TCC, other malignant diseases, or non-malignant urogenital
conditions will be provided.
Urine samples used in the study will be collected immediately prior to the urological
evaluation procedure and stored at -80 oC. Urine samples will be sent to sponsor and remain
at -80o C until analysis.
Clinical Data Collection:
All subject and clinical information will be recorded on the form in section 9.3. Enrollment
Checklist and Case Report Form (CRF). Information regarding the history of hematuria and
urine cytology will be recorded. In addition, non-identifying information including age,
sex, race, smoking history, alcohol consumption, occupational exposure to chemicals or dyes,
history of urologic disorder or disease, history of irritative voiding symptoms, history of
urinary tract infection, history of pelvic irradiation, and analgesic abuse will be
recorded. The Investigators will also be asked to provide information from the subjects'
medical records for up to one (1) year after their enrollment and sample collection. In
particular, diagnosis of TCC, other malignant diseases, or non-malignant urogenital
conditions will be provided.
Inclusion Criteria:
- Patients who are at least twenty-five (25) years of age with hematuria, dysuria or
other irritative voiding symptoms, without evidence of other causative factors such
as infections or stones.
Exclusion Criteria:
- Females who are pregnant (ascertained by history)
- Females who are menstruating or within three (3) days of their last menstruation
- Patients who have undergone invasive procedures of the urogenital tract in the past
two (2) months
- Patients with a history of transitional cell carcinoma (TCC) of the urinary tract
We found this trial at
1
site
Staten Island University Hospital Staten Island University Hospital is a 714-bed, specialized teaching hospital located...
Click here to add this to my saved trials
